This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Apoptosis
The apoptosis report part comprises defined and up to d ate deve lopment strategies for 171 apoptotic drugs in oncology (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. This report part extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target strategies, and assesses them in 53 different cancer indications.
This part is based on the following publication:
Apoptotic Therapeutics in Oncology – Where to Commercialize?

Part II: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.
This part is based on the following publicat ion:
Protein Kinase Therapeutics in Oncology – Where to Commercialize?

Part III: Antibodies
The antibody report part comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. This report part extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target strategies, and assesses them in 69 different cancer indications.
This part is based on the following publication:
Antibody Drug Target Atlas in Oncology – Where to Commercialize in a Crowded Market Place?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portf olio pro ducts. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area st…

Read more here: Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Antibodies.

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Angiogenesis
The angiogenesis report part comprises defi ned and up to date development strategies for 123 anti-angiogenesis drugs in oncology within the portfolio of 90 investigators, from Preclinical to Marketed. This report part extensively analyses 108 identified targets of angiogenesis drugs, organized into 88 drug target strategies, and assesses them in 44 different cancer indications
This part is based on the following publication:
Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology

Part II: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.
Th is part is based on the following publication:
Protein Kinase Therapeutics in Oncology – Where to Commercialize?

Part III: Antibodies
The antibody report part comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. This report part extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target strategies, and assesses them in 69 different cancer indications.
This part is based on the following publication:
Antibody Drug Target Atlas in Oncology – Where to Commercialize in a Crowded Market Place?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to develop ment str ategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area st…

Read more here: Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies.

This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strateg ies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.
This part is based on the following publication:
Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning – High Unmet Medical Need but Where to Target?

Part II: Prostate Cancer
The prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer.
T his part is based on the following publication:
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market

Part III: Apoptosis
The apoptosis report part comprises defined and up to date development strategies for 171 apoptotic drugs in oncology (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. This report part extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target strategies, and assesses them in 53 different cancer indications.
This part is based on the following publication:
Apoptotic Therapeutics in Oncology – Where to Commercialize?

The report is written for you to understand and assess the impact of co mpetitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting developmen t of int egrative molecule, pathway and disease area st…

Read more here: Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis.

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma report part comprises defined and up to date development strategies for 124 melanoma drugs within the port folio of 95 investigators, from Preclinical to Marketed. This report part extensively analyses 118 identified targets of melanoma drugs, organized into 94 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Currently Druggable in Melanoma: A Drug Target Competitive Analysis

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.
This part is based on the following publication:
Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning – High Unmet Medical Need but Where to Target?

Part III: Antibodies
The antibody report part comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. This report part extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target strategies, and assesses them in 69 different cancer indications.
This part is based on the following publication:
Antibody Drug Target Atlas in Oncology – Where to Commercialize in a Crowded Market Place?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area st…

Read more here: Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies.

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part includes defined and up to date development strategies for 176 lymphoma therape utic dru gs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications of lymphoma (B-cell lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, T-cell lymphoma and Lymphoma (general)). This report part extensively analyses 124 identified targets of lymphoma drugs, organized into 109 drug target strategies, and assesses them in lymphoma.
This part is based on the following publication:
Lymphoma Drug Development Strategies at Work – Define Your Competition

Part II: Prostate Cancer
The prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug targ et strat egies, and assesses them in prostate cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market

Part III: Cancer Vaccines
The cancer vaccines report part comprises defined and up to date development strategies for 109 cancer vaccines within the portfolio of 71 investigators, from Preclinical to Marketed. This report part extensively analyses 75 identified targets of cancer vaccines drugs, organized into 66 drug target strategies, and assesses them in 37 different cancer indications.
This part is based on the following publication:
Cancer Vaccines: Aim and Shoot

The report is written for you to understand and assess the impact of competitor entry a nd corre sponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecul e, pathway and disease area st…

Read more here: Triple Analysis: Lymphoma, Prostate Cancer and Cancer Vaccines.

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part includes defined and up to date development strateg ies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications of lymphoma (B-cell lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, T-cell lymphoma and Lymphoma (general)). This report part extensively analyses 124 identified targets of lymphoma drugs, organized into 109 drug target strategies, and assesses them in lymphoma.
This part is based on the following publication:
Lymphoma Drug Development Strategies at Work – Define Your Competition

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreati c cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.
This part is based on the following publication:
Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning – High Unmet Medical Need but Where to Target?

Part III: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.
This part is based on the following publication:
Pr otein Ki nase Therapeutics in Oncology – Where to Commercialize?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Prov iding you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area st…

Read more here: Triple Analysis: Lymphoma, Pancreatic Cancer and Protein Kinase Inhibitors.

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorect al cancer report part comprises defined and up to date development strategies for 156 colorectal cancer drugs within the portfolio of 108 investigators, from Preclinical to Marketed. This report part extensively analyses 120 identified targets of colorectal cancer drugs, organized into 105 drug target strategies, and assesses them in colorectal cancer.
This part is based on the following publication:
Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis

Part II: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 diff erent ca ncer indications.
This part is based on the following publication:
Protein Kinase Therapeutics in Oncology – Where to Commercialize?

Part III: Peptides
The peptide report part comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. This report part extensively analyses 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications.
This part is based on the following publication:
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathwa y and di sease area st…

Read more here: Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides.

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Colorectal Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer
The breast cancer report part comprises defined and up to date development strategies for 405 breast canc er drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer.
This part is based on the following publication:
Portfolio Analytics and Planning in the Breast Cancer Pipeline – Change is Around the Corner in a Highly Competitive Market Place

Part II: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 156 colorectal cancer drugs within the portfolio of 108 investigators, from Preclinical to Marketed. This report part extensively analyses 120 identified targets of colorectal cancer drugs, organized into 105 drug target strategies, and assesses them in colorectal cancer.
This p art is b ased on the following publication:
Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis

Part III: Peptides
The peptide report part comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. This report part extensively analyses 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications.
This part is based on the following publication:
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to developm ent strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disea se area st…

Read more here: Triple Analysis: Breast Cancer, Colorectal Cancer and Peptides.

These funny skype smileys are perfect for adding a little spice to your chats

This seems to have lots of information about photo frames and decorative picture frames. I think my favourite part is about the mosaic picture frames. It even has some great video about how to make your own.

Well worth checking out.